An End-to-End Pharmaceutical Development Pathway to Rapidly Bring Poorly Soluble New Chemical Entities to the Market

3/22/2022 14:30 - 15:00

  • Pharmaceutical development pathway integrating patient needs, development considerations and physico-chemical/biopharmaceutical compound profile
  • Integrated CMC platform from developability assessment, formulation design and process optimization leading to a robust commercial dosage form
  • Case studies showcasing how an integrated CMC platform can accelerate timelines

Alexandre Gil , Ph.D., SVP, Pharmaceutical Development Services, WuXi STA